Chemotherapy-Induced Neuropathy

Clinics in Podiatric Medicine and Surgery

Volumn 23, Issue 3, 2006, Pages 637-649

  Rosson, Gedge D ^a  

^a Division of Plastic and Reconstructive Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BORTEZOMIB; CARBAMAZEPINE; CISPLATIN; DEXTROMETHORPHAN; DOCETAXEL; DULOXETINE; GABAPENTIN; IXABEPILONE; KETAMINE; LAMOTRIGINE; LEVODOPA; LIDOCAINE; LINEZOLID; MEXILETINE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXALIPLATIN; PACLITAXEL; PHENYTOIN; PROTEASOME INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; SURAMIN; THALIDOMIDE; TOPIRAMATE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VINCRISTINE; VINCRISTINE SULFATE;

AGING; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CARPAL TUNNEL SYNDROME; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; DIABETES MELLITUS; DRUG MECHANISM; ELECTRODIAGNOSIS; ELECTROMYOGRAM; ERYTHEMA NODOSUM LEPROSUM; FATIGUE; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HUMAN; HYPERSENSITIVITY REACTION; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; OTOTOXICITY; OVARY CANCER; PARANEOPLASTIC SYNDROME; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; QUALITY OF LIFE; RAT STRAIN; REVIEW; SPINAL GANGLION; WALDENSTROEM MACROGLOBULINEMIA;

ANIMALS; ANTINEOPLASTIC AGENTS; DECOMPRESSION, SURGICAL; HUMANS; NERVE COMPRESSION SYNDROMES; PERIPHERAL NERVES; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS;

EID: 33745888443     PISSN: 08918422     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpm.2006.04.009     Document Type: Review

References (77)

1. Visovsky C. Chemotherapy-induced peripheral neuropathy. Cancer Invest 21 3 (2003) 439-451
2. Forman A.D. Peripheral neuropathy and cancer. Curr Oncol Rep 6 1 (2004) 20-25
3. Ocean A.J., and Vahdat L.T. Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 12 9 (2004) 619-625
4. Quasthoff S., and Hartung H.P. Chemotherapy-induced peripheral neuropathy. J Neurol 249 1 (2002) 9-17
5. Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol 1 4,Suppl 2 (2003) 18-24
6. Weimer L.H. Medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep 3 1 (2003) 86-92
7. Perkins B.A., Olaleye D., and Bril V. Carpal tunnel syndrome in patients with diabetic polyneuropathy. Diabetes Care 25 3 (2002) 565-569
8. Dellon A.L. Measuring peripheral nerve function: electrodiagnostic versus neurosensory testing. Atlas Hand Clin 10 1 (2005) 1-31
9. Tanner K.D., Levine J.D., and Topp K.S. Microtubule disorientation and axonal swelling in unmyelinated sensory axons during vincristine-induced painful neuropathy in rat. J Comp Neurol 395 4 (1998) 481-492
10. Legha S.S. Vincristine neurotoxicity. Pathophysiology and management. Med Toxicol 1 6 (1986) 421-427
11. Peltier A.C., and Russell J.W. Recent advances in drug-induced neuropathies. Curr Opin Neurol 15 5 (2002) 633-638
12. Kedar A., Cohen M.E., and Freeman A.I. Peripheral neuropathy as a complication of cis-dichlorodiammineplatinum(II) treatment: a case report. Cancer Treat Rep 62 5 (1978) 819-821
13. Cersosimo R.J. Cisplatin neurotoxicity. Cancer Treat Rev 16 4 (1989) 195-211
14. Thompson S.W., Davis L.E., Kornfeld M., et al. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 54 7 (1984) 1269-1275
15. Mollman J.E. Cisplatin neurotoxicity. N Engl J Med 322 2 (1990) 126-127
16. Cavaletti G., Bogliun G., Marzorati L., et al. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann Oncol 15 9 (2004) 1439-1442
17. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 30 4,Suppl 15 (2003) 5-13
18. Cersosimo R.J. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 39 1 (2005) 128-135
19. Cavaletti G., Tredici G., Braga M., et al. Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp Neurol 133 1 (1995) 64-72
20. Sahenk Z., Barohn R., New P., et al. Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. Arch Neurol 51 7 (1994) 726-729
21. Rowinsky E.K., Eisenhauer E.A., Chaudhry V., et al. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20 4,Suppl 3 (1993) 1-15
22. Pronk L.C., Stoter G., and Verweij J. Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects. Cancer Treat Rev 21 5 (1995) 463-478
23. Hilkens P.H., Verweij J., Stoter G., et al. Peripheral neurotoxicity induced by docetaxel. Neurology 46 1 (1996) 104-108
24. Verweij J., Clavel M., and Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 5 6 (1994) 495-505
25. Shapiro C.L., and Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 344 26 (2001) 1997-2008
26. Chaudhry V., Eisenberger M.A., Sinibaldi V.J., et al. A prospective study of suramin-induced peripheral neuropathy. Brain 119 Pt 6 (1996) 2039-2052
27. Russell J.W., Gill J.S., Sorenson E.J., et al. Suramin-induced neuropathy in an animal model. J Neurol Sci 192 1,2 (2001) 71-80
28. Ghobrial I.M., and Rajkumar S.V. Management of thalidomide toxicity. J Support Oncol 1 3 (2003) 194-205
29. D'Amato R.J., Loughnan M.S., Flynn E., et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91 9 (1994) 4082-4085
30. Raje N., and Anderson K. Thalidomide-a revival story. N Engl J Med 341 21 (1999) 1606-1609
31. Coleman M., Leonard J., Lyons L., et al. Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Semin Oncol 30 2 (2003) 270-274
32. Chaudhry V., Cornblath D.R., Corse A., et al. Thalidomide-induced neuropathy. Neurology 59 12 (2002) 1872-1875
33. Briani C., Zara G., Rondinone R., et al. Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus. Neurology 62 12 (2004) 2288-2290
34. Cavaletti G., Beronio A., Reni L., et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology 62 12 (2004) 2291-2293
35. Apfel S.C., and Zochodne D.W. Thalidomide neuropathy: too much or too long?. Neurology 62 12 (2004) 2158-2159
36. Dimopoulos M.A., and Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 117 7 (2004) 508-515
37. Aghajanian C., Soignet S., Dizon D.S., et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8 8 (2002) 2505-2511
38. Maki R.G., Kraft A.S., Scheu K., et al. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer 103 7 (2005) 1431-1438
39. Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 26 (2003) 2609-2617
40. Jagannath S., Barlogie B., Berenson J., et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127 2 (2004) 165-172
41. Goy A., Younes A., McLaughlin P., et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23 4 (2005) 667-675
42. Eng C., Kindler H.L., Nattam S., et al. A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Ann Oncol 15 6 (2004) 928-932
43. Low J.A., Wedam S.B., Lee J.J., et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 23 12 (2005) 2726-2734
44. Galsky M.D., Small E.J., Oh W.K., et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 23 7 (2005) 1439-1446
45. Chong P.H., Boskovich A., Stevkovic N., et al. Statin-associated peripheral neuropathy: review of the literature. Pharmacotherapy 24 9 (2004) 1194-1203
46. Bressler A.M., Zimmer S.M., Gilmore J.L., et al. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 4 8 (2004) 528-531
47. Cunha B.A. Antibiotic side effects. Med Clin North Am 85 1 (2001) 149-185
48. Brew B.J. The peripheral nerve complications of human immunodeficiency virus (HIV) infection. Muscle Nerve 28 5 (2003) 542-552
49. Honnorat J., and Cartalat-Carel S. Advances in paraneoplastic neurological syndromes. Curr Opin Oncol 16 6 (2004) 614-620
50. Altaha R., and Abraham J. Paraneoplastic neurologic syndrome associated with occult breast cancer: a case report and review of literature. Breast J 9 5 (2003) 417-419
51. Rojas-Marcos I., Rousseau A., Keime-Guibert F., et al. Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer. Medicine (Baltimore) 82 3 (2003) 216-223
52. Koller H., Kieseier B.C., Jander S., et al. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 352 13 (2005) 1343-1356
53. Backonja M., Beydoun A., Edwards K.R., et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280 21 (1998) 1831-1836
54. Beydoun A., and Backonja M.M. Mechanistic stratification of antineuralgic agents. J Pain Symptom Manage 25 5 Suppl (2003) S18-S30
55. Wolfe G.I., and Trivedi J.R. Painful peripheral neuropathy and its nonsurgical treatment. Muscle Nerve 30 1 (2004) 3-19
56. Gilron I., Bailey J.M., Tu D., et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 352 13 (2005) 1324-1334
57. Tassler P., Dellon A.L., Lesser G.J., et al. Utility of decompressive surgery in the prophylaxis and treatment of cisplatin neuropathy in adult rats. J Reconstr Microsurg 16 6 (2000) 457-463
58. Dellon A.L., Swier P., Maloney Jr. C.T., et al. Chemotherapy-induced neuropathy: treatment by decompression of peripheral nerves. Plast Reconstr Surg 114 2 (2004) 478-483
59. Dellon A.L., Mackinnon S.E., and Seiler IV W.A. Susceptibility of the diabetic nerve to chronic compression. Ann Plast Surg 20 2 (1988) 117-119
60. Albers J.W., Brown M.B., Sima A.A., et al. Frequency of median mononeuropathy in patients with mild diabetic neuropathy in the early diabetes intervention trial (EDIT). Muscle Nerve 19 2 (1996) 140-146
61. Dellon A.L., Dellon E.S., and Seiler IV W.A. Effect of tarsal tunnel decompression in the streptozotocin-induced diabetic rat. Microsurgery 15 4 (1994) 265-268
62. Kale B., Yuksel F., Celikoz B., et al. Effect of various nerve decompression procedures on the functions of distal limbs in streptozotocin-induced diabetic rats: further optimism in diabetic neuropathy. Plast Reconstr Surg 111 7 (2003) 2265-2272
63. Belgrade M.J., and Lev B.I. Diabetic neuropathy. Helping patients cope with their pain. Postgrad Med 90 5 (1991) 263-270
64. Vinik A.I. Advances in diabetes for the millennium: new treatments for diabetic neuropathies. MedGenMed 6 2 (2004) 13
65. Dellon A.L. Treatment of symptomatic diabetic neuropathy by surgical decompression of multiple peripheral nerves. Plast Reconstr Surg 89 4 (1992) 689-697 [discussion: 698-9]
66. Wieman T.J., and Patel V.G. Treatment of hyperesthetic neuropathic pain in diabetics. Decompression of the tarsal tunnel. Ann Surg 221 6 (1995) 660-664 [discussion: 664-5]
67. Aszmann O.C., Kress K.M., and Dellon A.L. Results of decompression of peripheral nerves in diabetics: a prospective, blinded study. Plast Reconstr Surg 106 4 (2000) 816-822
68. Caffee H.H. Treatment of diabetic neuropathy by decompression of the posterior tibial nerve. Plast Reconstr Surg 106 4 (2000) 813-815
69. Tambwekar D.S. Extended neurolysis of the posterior tibial nerve to improve sensation in diabetic neuropathic feet. Plast Reconstr Surg 108 5 (2001) 1452-1453
70. Wood W.A., and Wood M.A. Decompression of peripheral nerves for diabetic neuropathy in the lower extremity. J Foot Ankle Surg 42 5 (2003) 268-275
71. Biddinger K.R., and Amend K.J. The role of surgical decompression for diabetic neuropathy. Foot Ankle Clin 9 2 (2004) 239-254
72. Lee C.H., and Dellon A.L. Prognostic ability of Tinel sign in determining outcome for decompression surgery in diabetic and nondiabetic neuropathy. Ann Plast Surg 53 6 (2004) 523-527
73. Aszmann O., Tassler P.L., and Dellon A.L. Changing the natural history of diabetic neuropathy: incidence of ulcer/amputation in the contralateral limb of patients with a unilateral nerve decompression procedure. Ann Plast Surg 53 6 (2004) 517-522
74. Singh N., Armstrong D.G., and Lipsky B.A. Preventing foot ulcers in patients with diabetes. JAMA 293 2 (2005) 217-228
75. Haupt W.F., Wintzer G., Schop A., et al. Long-term results of carpal tunnel decompression. Assessment of 60 cases. J Hand Surg [Br] 18 4 (1993) 471-474
76. Ozkul Y., Sabuncu T., Kocabey Y., et al. Outcomes of carpal tunnel release in diabetic and non-diabetic patients. Acta Neurol Scand 106 3 (2002) 168-172
77. Mondelli M., Padua L., Reale F., et al. Outcome of surgical release among diabetics with carpal tunnel syndrome. Arch Phys Med Rehabil 85 1 (2004) 7-13